Naples, Italy

Carmine Settembre

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Carmine Settembre: Innovator in Therapeutic Applications

Introduction

Carmine Settembre is a notable inventor based in Naples, Italy. He has made significant contributions to the field of molecular biology, particularly in the development of therapeutic applications for various diseases. With a total of two patents to his name, Settembre's work focuses on innovative solutions that address critical health challenges.

Latest Patents

Settembre's latest patents include "TFEB variants and uses thereof." This invention pertains to TFEB-related molecules, such as variants, mutants, truncated proteins, and chimeras that are constitutively localized in the nucleus of a eukaryotic cell. These molecules have therapeutic applicability in disorders that require the induction of the cell autophagic/lysosomal system. This includes lysosomal storage disorders, neurodegenerative diseases, hepatic diseases, muscle diseases, and metabolic diseases.

Career Highlights

Carmine Settembre is associated with Fondazione Telethon, an organization dedicated to funding research for genetic diseases. His work at this foundation has allowed him to collaborate with leading experts in the field, further enhancing his contributions to medical science.

Collaborations

Settembre has worked alongside notable colleagues such as Andrea Ballabio and Diego Luis Medina Sanabria. These collaborations have enriched his research and expanded the impact of his inventions.

Conclusion

Carmine Settembre's innovative work in the field of molecular biology exemplifies the potential of scientific research to address complex health issues. His patents and collaborations highlight his commitment to advancing therapeutic applications for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…